# PRKN

Source: https://onco.cc/targets/prkn/  
OnCo record `prkn` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PRKN (E3 ubiquitin-protein ligase parkin) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer and Ovarian cancer.

## Summary

Functions within a multiprotein E3 ubiquitin ligase complex, catalysing the covalent attachment of ubiquitin moieties onto substrate proteins. Substrates include SYT11 and VDAC1. Other substrates are BCL2, CCNE1, GPR37, RHOT1/MIRO1, MFN1, MFN2, STUB1, SNCAIP, SEPTIN5, TOMM20, USP30, ZNF746, MIRO1 and AIMP2.

CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Phosphatidylinositide 3-Kinase Inhibitor. Open Targets scores its association with cancer at 0.66 (direct and indirect evidence; datatypes literature 0.99, genetic association 0.85).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: parkin RBR E3 ubiquitin protein ligase; E3 ubiquitin-protein ligase parkin; AR-JP; parkin; PARK2
- Tags: cancer-genes-wave
- Symbol: PRKN
- Class: transcription
- Biology: Functions within a multiprotein E3 ubiquitin ligase complex, catalysing the covalent attachment of ubiquitin moieties onto substrate proteins. Substrates include SYT11 and VDAC1. Other substrates are BCL2, CCNE1, GPR37, RHOT1/MIRO1, MFN1, MFN2, STUB1, SNCAIP, SEPTIN5, TOMM20, USP30, ZNF746, MIRO1 and AIMP2. Mediates monoubiquitination as well as 'Lys-6', 'Lys-11', 'Lys-48'-linked and 'Lys-63'-linked polyubiquitination of substrates depending on the context. Participates in the removal and/or detoxification of abnormally folded or damaged protein by mediating 'Lys-63'-linked polyubiquitination of misfolded proteins such as PARK7: 'Lys-63'-linked polyubiquitinated misfolded proteins are then recognised by HDAC6, leading to their recruitment to aggresomes, followed by degradation. Mediates 'Lys-63'-linked polyubiquitination of a 22 kDa O-linked glycosylated isoform of SNCAIP, possibly playing a role in Lewy-body formation. Location: Cytoplasm, cytosol; Nucleus; Endoplasmic reticulum; Mitochondrion (UniProt). Locus 6q26 (HGNC).
- Where found: Lung cancer: Open Targets association 0.58 with lung cancer (MONDO_0008903); Ovarian cancer: Open Targets association 0.57 with ovarian cancer (MONDO_0008170)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:8607: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8607
- UniProt O60260: https://www.uniprot.org/uniprotkb/O60260/entry
- NCBI Gene 5071: https://www.ncbi.nlm.nih.gov/gene/5071
- Ensembl ENSG00000185345: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185345

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)

---
JSON: https://onco.cc/api/v1/entities/prkn.json